Autism Science Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2014
NCT01970345
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

mecasermin (increlex) (1 trial)

Drugs in Other Trials (1)

propranolol (inderal) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Child Development Disorders, Pervasive (Phase 2)

Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2